Fluorescein diacetate vital staining allows earlier diagnosis of rifampicin-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 9, 2012, Pages 1174-1179

  Van Deun, Armand ^a,b   Maug, A K J ^c   Hossain, A ^a   Gumusboga, M ^a   De Jong, B C ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^c Damien Foundation Bangladesh   (Bangladesh)

Author keywords

Culture; Drug susceptibility testing; Microscopy; Multidrug resistance; Viability

Indexed keywords

FLUORESCEIN DIACETATE; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG TREATMENT FAILURE; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; HUMAN; INTERMETHOD COMPARISON; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; VITAL STAIN;

ANTIBIOTICS, ANTITUBERCULAR; BANGLADESH; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EARLY DIAGNOSIS; FLUORESCEINS; FLUORESCENT DYES; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, FLUORESCENCE; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SPUTUM; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84865269466     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0166     Document Type: Article

References (15)

1. Rieder H L. Sputum smear conversion during directly observed treatment for tuberculosis. Tubercle Lung Dis 1996; 77: 124-129. (Pubitemid 26139144)
2. Al-Moamary M S, Black W, Bessuille E, Elwood R K, Vedal S. The significance of the persistent presence of acid-fast bacilli in sputum smears in pulmonary tuberculosis. Chest 1999; 116: 726-731. (Pubitemid 29428492)
3. Telzak E E, Fazal B A, Pollard C L, Turett G S, Justman J E, Blum S. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. Clin Infect Dis 1997; 25: 666-670. (Pubitemid 127774281)
4. Hamid Salim A, Aung K J M, Hossain M A, Van Deun A. Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB. Int J Tuberc Lung Dis 2006; 10: 1248-1254. (Pubitemid 44713479)
5. Van Deun A, Kya Jai Maug A, Halim M A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
6. Van Deun A, Aung K J M, Chowdhury S, et al. Drug susceptibility of Mycobacterium tuberculosis in a rural area of Bangladesh and its relevance to the national treatment regimens. Int J Tuberc Lung Dis 1999; 3: 143-148. (Pubitemid 29151818)
7. Van Deun A, Salim A H, Daru P, et al. Drug resistance monitoring: combined rates may be the best indicator of programme performance. Int J Tuberc Lung Dis 2004; 8: 23-30.
8. Hamid Salim M A, Uplekar M, Daru P, Aung M, Declerq E, Lönnroth K. Turning liabilities into resources: informal village doctors and tuberculosis control in Bangladesh. Bull World Health Organ 2006; 84: 479- 484.
9. Mitchison D A, Allen B W, Carrol L, Dickinson J M, Aber V R. A selective oleic acid albumin agar medium for tubercle bacilli. J Med Microbiol 1972; 5: 165-175.
10. Giampaglia C M S, Martins M C, Chimara E, et al. Differentiation of Mycobacterium tuberculosis from other mycobacteria with ñ-nitrobenzoic acid using MGIT960. Int J Tuberc Lung Dis 2007; 11: 803-807. (Pubitemid 47056992)
11. Rieder H L, Van Deun A, Kam K M, Kim S J, Chonde T M, Trébucq A, Urbanczik R. Priorities for tuberculosis bacteriology services in low-income countries. 2nd ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 2007.
12. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
13. Dawson D J, Blacklock Z M, Hayward A J, Walsh M J. Differential identification of mycobacteria in smears of sputum. Tubercle 1981; 62: 257-262. (Pubitemid 12193665)
14. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 4th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 2009: pp 1-147.
15. Aung K J M, Declerq E, Ali Md A, et al. Extension of the intensive phase reduces relapse but not failure in a regimen with rifampicin throughout. Int J Tuberc Lung Dis 2012; 16: 455-461.